Heterocyclic beta-3 adrenergic receptor agonists

US6605618B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Mark Anthony Ashwell · Plainsboro, US
• William Ronald Solvibile · Monmouth Junction, US
• Dominick Anthony Quagliato · Edison, US
• Albert J. Molinari · Princeton, US

Key dates

• Filing date: Jul 2, 2002
• Grant date: Aug 12, 2003
• Expiry date: Jul 2, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention provides compounds of Formula I having the structure wherein,  U, V, W, X, and Y are as defined hereinbefore,or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.